174 related articles for article (PubMed ID: 35377770)
1. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
Chan A; Silván CV
Neurodegener Dis Manag; 2022 Jun; 12(3):141-154. PubMed ID: 35377770
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.
Haupts MR; Essner U; Mäurer M
Neurodegener Dis Manag; 2024 Feb; 14(1):11-20. PubMed ID: 38318862
[TBL] [Abstract][Full Text] [Related]
3. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
Paul F; Silván CV
Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Nicholas J; Lublin F; Klineova S; Berwaerts J; Chinnapongse R; Checketts D; Javaid S; Steinerman JR
Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
[TBL] [Abstract][Full Text] [Related]
5. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
[TBL] [Abstract][Full Text] [Related]
6. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
[TBL] [Abstract][Full Text] [Related]
7. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
8. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
9. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
Conte A; Vila Silván C
Neurodegener Dis; 2021; 21(3-4):55-62. PubMed ID: 34731865
[TBL] [Abstract][Full Text] [Related]
10. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
[TBL] [Abstract][Full Text] [Related]
12. Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria.
Guger M; Hatschenberger R; Leutmezer F
Brain Behav; 2023 Apr; 13(4):e2947. PubMed ID: 36934456
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Riva N; Mora G; Sorarù G; Lunetta C; Ferraro OE; Falzone Y; Leocani L; Fazio R; Comola M; Comi G;
Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
[TBL] [Abstract][Full Text] [Related]
15. A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.
Patti F; Chisari CG; Fernández Ó; Sarroca J; Ferrer-Picón E; Hernández Vicente F; Vila Silván C
Eur J Neurol; 2022 Sep; 29(9):2744-2753. PubMed ID: 35590453
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
Prieto González JM; Vila Silván C
Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
[TBL] [Abstract][Full Text] [Related]
17. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Bazinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
[TBL] [Abstract][Full Text] [Related]
18. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
19. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Basinski H; Jensen HB; Stenager E
Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
[TBL] [Abstract][Full Text] [Related]
20. Cannabis and multiple sclerosis.
Fragoso YD; Carra A; Macias MA
Expert Rev Neurother; 2020 Aug; 20(8):849-854. PubMed ID: 32515670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
